Responses
Clinical/translational cancer immunotherapy
Original research
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Compose a Response to This Article
Other responses
No responses have been published for this article.
